Novartis Ag's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Novartis Ag (NVS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Novartis Ag vs Its Competitors
- TTM: Trailing 12-month revenue of 56,674M vs 769,081M combined for its competitors (6.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+47.9%) for its tracked peer group.
- Growth: Novartis Ag generated 9.6% revenue growth year over year in Q4 2025, vs 7.1% for its competitors combined.
- Profitability: Its 24.6% net margin compares with 13.9% for the peer group.
- Scale: Novartis Ag ranks #6 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 5.4% of industry market cap.
- Peer revenue share: Novartis Ag accounted for 16.6% of combined revenue among its tracked peer group, up from 16.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.75M compares with $0.87M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NVS Sales vs. its Competitors, Q4 2025
Novartis Ag reported revenue growth of 9.57 % year on year in Q4 2025, above its competitors' combined revenue growth of 7.11 %.
With a net margin of 24.64 %, Novartis Ag achieved higher profitability than its competitors (13.94 %).
Novartis Ag generated 16.62 % of the combined sales of its peer group, up from 16.31 % a year earlier.
Novartis Ag vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Novartis Ag reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Novartis Ag and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Novartis Ag | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (91) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Novartis Ag's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 9.6% for Novartis Ag. Novartis Ag's share of combined industry revenue moved from 10.77% to 10.84%, a gain of 0.07 percentage points.
Novartis Ag's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Novartis Ag | Yes | Yes | Yes | No |
| Competitors combined (269) | ||||
| High-Confidence Competitors (115) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (7 of 7) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NVS Stock Performance relative to its Competitors
NVS Stock Performance relative to High-Confidence Competitors
NVS Stock Performance relative to Similar-Size Competitors
NVS Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Chimerix Inc | 282.9% | Outperformed |
| 3 | Gt Biopharma Inc | 282.9% | Outperformed |
| 4 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 5 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Novartis Ag's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Novartis Ag's Comment on Competition and Industry Peers
Publicly Traded Peers of Novartis Ag
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Novartis Ag |
316,573.15 | 56,674.00 |
 Eli Lilly And Company |
1,221,912.11 | 86,462.00 |
 Johnson and Johnson |
666,802.75 | 99,335.00 |
 Beone Medicines Ltd |
582,951.40 | 6,128.24 |
 Abbvie Inc |
510,761.28 | 66,014.00 |
 Merck and Co Inc |
362,843.00 | 66,569.00 |
| SUBTOTAL | 5,655,546.22 | 863,893.41 |
Sign in to see all competitors of Novartis Ag.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Novartis Ag versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Novartis Ag's Competitors Named by the Company
Competitive relationships identified from Novartis Ag reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Autolus Therapeutics Plc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Cingulate Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Verona Pharma Plc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| Harrow Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Codexis inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Quantum Biopharma Ltd | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Organogenesis Holdings Inc | Company report | 85% |
| Blue Water Vaccines Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Orchestra Biomed Holdings Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Neonc Technologies Holdings Inc | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Adverum Biotechnologies Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Crinetics Pharmaceuticals Inc | Company report | 85% |
| Vigil Neuroscience Inc | Company report | 85% |
| Celcuity Inc | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| Vaccinex Inc | Company report | 85% |
| Acorda Therapeutics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| ACOR | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Krystal Biotech Inc | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| IMAB | Company report | 85% |
| Cellectis S a | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Alimera Sciences Inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Genprex Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Pmv Pharmaceuticals Inc | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Aytu Biopharma Inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| RENB | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Kalvista Pharmaceuticals Inc | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| APDN | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Lantheus Holdings Inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Perspective Therapeutics Inc | Company report | 85% |
| Foghorn Therapeutics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Optinose Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Range Impact Inc | Company report | 85% |
| Zyversa Therapeutics Inc | Company report | 85% |
| Organon and Co | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Sanofi | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Bausch and Lomb Corp | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Lianbio | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Orchard Therapeutics Plc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Spero Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Rocket Pharmaceuticals Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Dr Reddy s Laboratories Limited | Company report | 85% |
| Glaukos Corp | Company report | 85% |
| Ocular Therapeutix Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Novartis Ag's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Novartis Ag's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Novartis Ag's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Novartis Ag | 316,573 | 752,973 | 185,566 |
| Eli Lilly And Company | 1,221,912 | 1,729,240 | 551,594 |
| Johnson and Johnson | 666,803 | 705,504 | 114,311 |
| Beone Medicines Ltd | 582,951 | 510,686 | 54,642 |
| Abbvie Inc | 510,761 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,843 | 887,587 | 42,267 |
| PEERS TOTAL | 5,338,973 | 867,645 | 96,386 |
Novartis Ag's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Novartis Ag's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Novartis Ag's industry classification, broader than the peer set above. Market cap in millions of $.Novartis Ag ranks #6 of 496 companies by market capitalization in its industry, holding 5.37 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 320,542 | 5.37 % |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
Market cap and industry share for the rest of Novartis Ag's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Novartis Ag's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 58.05 % |
| 2 | Johnson and Johnson | 681,032 | 49.36 % |
| 3 | Beone Medicines Ltd | 589,304 | 26.61 % |
| 4 | Abbvie Inc | 528,644 | 38.26 % |
| 5 | Merck and Co Inc | 1,234 | 12.3% |
| 6 | Novartis Ag | 320,542 | 31.16 % |
| 7 | Abbott Laboratories | 1,234 | 12.3% |
| 8 | Novo Nordisk A | 1,234 | 12.3% |
| 9 | Pfizer Inc | 1,234 | 12.3% |
| 10 | Astrazeneca Plc | 1,234 | 12.3% |
| 11 | Vertex Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Novartis Ag's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Novartis Ag's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 75.83 % | 37.69 % (avg) | +38.1 pp |
| Operating Margin | 31.13 % | industry median | +26.8 pp |
| EBITDA Margin | 30.87 % | -6.49 % (avg) | +37.4 pp |
| Capital Intensity (Capex / Revenue) | 2.73 % | 7.58 % (avg) | -4.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Novartis Ag's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 18.3x | 26.6x | -8.3x |
| EV / EBITDA | 14.0x | 15.9x | -1.9x |
| P/B | 5.5x | 4.3x | +1.2x |
| Return on Equity | 30.00 % | industry aggregate | 9.88 % |
| Return on Invested Capital | 11.22 % | -9.93 % (avg) | 21.15 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Novartis Ag's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -9.97 % | 10.85 % | 9.57 % |
| Operating Margin | 20.94 % | 28.12 % | 31.13 % |
| Return on Invested Capital | 6.67 % | 9.95 % | 11.22 % |
| P/E | 13.6x | 18.2x | 18.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Novartis Ag's Strategic Group Map
Novartis Ag is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Novartis Ag's trailing-12-month revenue growth of 9.6% and operating margin of 31.1% compares with an average of 7.8% growth and 28.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Novartis Ag sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Novartis Ag's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Novartis Ag falls in the Dog quadrant: relative market share of 0.25x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Novartis Ag's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.73 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Novartis Ag's dedicated Suppliers and Customers pages, not here.
Novartis Ag's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Novartis Ag falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Novartis Ag's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 26.8 points above the industry median.
- Return on equity 9.9 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.25x).
Opportunities
- Trades at a lower P/E than the industry average (18.3x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (50.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Novartis Ag's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Novartis Ag's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +9.7 % | -1.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Novartis Ag's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Novartis Ag's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Novartis Ag's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Novartis Ag | 22.64 | 5.59 |
| Eli Lilly And Company | 44.41 | 14.13 |
| Johnson and Johnson | 41.20 | 6.71 |
| Beone Medicines Ltd | 880.11 | 95.13 |
| Abbvie Inc | 49.61 | 7.74 |
| Merck and Co Inc | 118.47 | 5.45 |
| PEERS AVERAGE | 54.57 | 6.55 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.